Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0058)
Name
Stigmasterol
Synonyms
STIGMASTEROL; 83-48-7; Stigmasterin; beta-Stigmasterol; Stigmasta-5,22-dien-3beta-ol; Stigmasta-5,22-dien-3-ol, (3b,22E)-; (24S)-5,22-Stigmastadien-3beta-ol; Stigmasta-5,22-dien-3-beta-ol; UNII-99WUK5D0Y8; Stigmasta-5,22-dien-3-ol, (3beta,22E)-; Delta5-Stigmasterol; .beta.-Stigmasterol; STIMASTEROL; 99WUK5D0Y8; CCRIS 7476; CHEBI:28824; HSDB 7683; (3beta,22E)-Stigmasta-5,22-dien-3-ol; NSC 8095; NSC-8095; EINECS 201-482-7; Wulzen anti-stiffness factor; Stigmasta-5,22-dien-3-ol, (3beta)-; Stigmasta-5,22E-dien-3beta-ol; DTXSID801015733; Delta5,22-Stigmastadien-3beta-ol; 5,22-Cholestadien-24-ethyl-3beta-ol; GUINEA-PIG-ANTI-STIFFNESS FACTOR; (22E)-stigmasta-5,22-dien-3beta-ol; .delta.5,22-Stigmastadien-3.beta.-ol; (3.beta.,22E)-Stigmasta-5,22-dien-3-ol; Stigmasta-5,22-dien-3-ol; MFCD00003630; (3S,8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 3beta-Hydroxy-24-ethyl-5,22-cholestadiene; Serposterol; b-stigmasterol; Stigmasta-5,22-dien-3.beta.-ol; D5-Stigmasterol; Stigmasterol, ~95%; STIGMASTEROL [MI]; STIGMASTEROL [HSDB]; SCHEMBL23999; .DELTA.5-STIGMASTEROL; STIGMASTEROL [WHO-DD]; stigmasta-5,22t-dien-3b-ol; CHEMBL400247; stigmasta-5,22-dien-3-b-ol; HCXVJBMSMIARIN-PHZDYDNGSA-N; DTXCID601473919; GLXC-13540; HY-N0131; (24S)-5,22-stigmastadien-3b-ol; BDBM50376364; HB4095; LMST01040123; s2361; STL570256; 24aFH-stigmasta-5,22t-dien-3b-ol; AKOS022168193; CS-7746; (24S)-Stigmast-5,22-dien-3beta-ol; (24xH)-stigmasta-5,22t-dien-3b-ol; 24-Ethyl-5,22-cholestadien-3beta-ol; (24aFH)-stigmasta-5,22t-dien-3b-ol; (24x)-ethylcholesta-5,22-dien-3b-ol; NCGC00142599-03; (3b,22E)-stigmasta-5,22-dien-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5S,E)-5-ethyl-6-methylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 14-((2E)(4S,1R)-4-ethyl-1,5-dimethylhex-2-enyl)(1S,5S,10S,11S,2R,14R,15R)-2,15 -dimethyltetracyclo[8.7.0.0<2,7>.0<11,15>]heptadec-7-en-5-ol; 24x-24-ethylcholest-5,22-dien-3b-ol; AS-15473; 24-Ethyl-5,22-cholestadien-3.beta.-ol; 5,22-Cholestadien-24beta-ethyl-3beta-ol; rac-(24xH)-stigmasta-5,22t-dien-3b-ol; STIGMASTEROL (CONSTITUENT OF PYGEUM); (24S)-24-Ethylcholesta-5,22-dien-3beta-ol; C05442; Q425004; STIGMASTEROL (CONSTITUENT OF PYGEUM) [DSC]; STIGMASTEROL (CONSTITUENT OF SAW PALMETTO); Q-201746; STIGMASTEROL (CONSTITUENT OF SAW PALMETTO) [DSC]; 3beta-HYDROXY-24-ETHYL-delta(SUP 5,22)-CHOLESTADIENE; 3.BETA.-HYDROXY-24-ETHYL-.DELTA.(SUP 5,22)-CHOLESTADIENE; Stigmasterol, certified reference material, 10 mg/mL in chloroform; 17-(4-ethyl-1,5-dimethyl-hex-2-enyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol

    Click to Show/Hide
Structure
Formula
C29H48O
IUPAC Name
(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
Canonical SMILES
CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C
InChI
InChI=1S/C29H48O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h8-10,19-21,23-27,30H,7,11-18H2,1-6H3/b9-8+/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1
InChIKey
HCXVJBMSMIARIN-PHZDYDNGSA-N
PubChem CID
5280794
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Knee osteoarthritis ICD-11: FA01
 Disease Info 
Responsed Regulator Sterol regulatory element-binding protein 2 Driver
 Regulator Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model ATDC-5 cells Teratocarcinoma Mus musculus CVCL_3894
Response regulation Stigmasterol (STM) attenuates chondrocyte injury induced by IL-1 by regulating ferroptosis via down-regulation of SREBF2, which suggests that STM may have potential as a novel therapeutic method for knee osteoarthritis.
References
Ref 1 Stigmasterol alleviates interleukin-1beta-induced chondrocyte injury by down-regulatingsterol regulatory element binding transcription factor 2 to regulateferroptosis. Bioengineered. 2021 Dec;12(2):9332-9340. doi: 10.1080/21655979.2021.2000742.